Table of ContentsIntroductionRead (pg. 5)Groundbreaking Drug Launches (Gepotidacin)Read (pg. 6)Donanemab (Kisunla)Read (pg. 7)Suzetrigine (JOURNAVX)Read (pg. 8)Orforglipron (LY-3502970/OWL 833)Read (pg. 9)Semaglutide/Cagrilintide (CagriSema)Read (pg. 10)Revakinagene taroretcel (Encelto)Read (pg. 11)Meloxicam/rizatriptan (SYMBRAVO)Read (pg. 12)Budesonide/formoterol/glycopyrrolate (Breztri Aerosphere)Read (pg. 13)Concizumab (Alhemo)Read (pg. 14)Deutivacaftor/tezacaftor/vanzacaftor (ALYFTREK)Read (pg. 15)Olezarsen (TRYNGOLZA)Read (pg. 16)Tabelecleucel (Ebvallo)Read (pg. 17)Groundbreaking Drug Launches: Notable mentionsRead (pg. 18)Patent Expirations and Market Impact (Sacubitril/ valsartan)Read (pg. 19)Rivaroxaban (Xarelto)Read (pg. 20)Empagliflozin (Jardiance)Read (pg. 21)Aclidinium bromide (Tudorza Pressair)Read (pg. 22)Aclidinium bromide/ formoterol (Duaklir Pressair)Read (pg. 23)ConclusionRead (pg. 24)ReferencesRead (pg. 27)Pharma Insight Reportshttps://adisinsight.springer.com/pharma-insight-reports